Skip to Content

Tyme Technologies Inc

Rating as of

Company Profile

Business Description

Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.

Contact
17 State Street, 7th Floor
New York, NY, 10004
T +1 212 461-2315
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2020
Fiscal Year End Mar 31, 2021
Stock Type
Employees 18